Quantum Pharma announces Lamda out-licensing

Quantum Pharma Plc

("Quantum" or the "Group")

Quantum Pharma announces Lamda out-licensing agreements

Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce a succession of out-licensing deals across Europe from its recently acquired division, Lamda.

A generic plus dossier containing an undisclosed Active Pharmaceutical Ingredient ("API"), which Lamda co-developed, has been out-licensed to a French-based pharmaceutical company in over 40 territories from which Lamda is receiving licensing fees and rights to future royalty income.

Lamda has also out-licensed a generic dossier for an undisclosed API to a pharmaceutical company for a fixed license fee with a royalty over five years once the product is licensed in Germany.

The continued commercialisation of the latent value held within Lamda's 100 plus projects is encouraging, and Quantum believes that Lamda will continue to develop as described at the time of acquisition.

Andrew Scaife, CEO of Quantum Pharma, said: "At the time of acquisition we stated that part of the upside potential within Lamda was its ability to out-licence products, and these initial two European out-licensing deals demonstrate that. These out-licences see Quantum's stated business plan for Lamda developing as anticipated, and we expect to see further deals in the coming months. Since IPO, Quantum has significantly diversified both its product portfolio and its infrastructure, and with this has come a number of potential new income streams and an increased platform of strategic partners in Europe."

- Ends -

For further information:

Media enquiries:

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical manufacturer, developer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through eight business units offering a portfolio of innovative and complementary products and services to primary and secondary care providers.

Colonis a product development business which takes niche pharmaceutical products through the regulatory pathway to achieve licensed and/or regulated status.

Lamda a full service contract development specialist with customers across Europe.

Quantum Pharmaceutical manufactures and supplies specials and special obtains for pharmacy chains, pharmaceutical wholesalers, hospitals and independent pharmacies in the UK.

Quantum Aseptic Services manufactures aseptically prepared sterile intravenous products, either individually for named patients or in batches.

UL Medicines sources and supplies unlicensed imported medicines and specials to hospitals, community pharmacies and wholesalers in the UK and overseas.

NuPharm offers product development, clinical trials product manufacture, and outsourced manufacture for solid and liquid dose batch-made specials and niche licensed medicines.

Biodose® a medicines delivery system that accommodates liquid and solid medication, supporting medicines administration and adherence for 50,000 patients, their carers and clinicians with Biodose Services® delivering pre-prepared medication regimes to care homes.

For further information, please visit www.quantumpharmagroup.com.